跳至主要内容
临床试验/JPRN-UMIN000018834
JPRN-UMIN000018834已完成未知

Efficacy and Safety of endoscopic ultrasound-guided ethanol ablation therapy for pancreatic neuroendocrine tumors: A Pilot Study - Ethanol ablation therapy for pancreatic neuroendocrine tumors

Okayama University Hospital0 个研究点目标入组 5 人开始时间: 2015年10月31日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
5

研究概览

简要总结

A total of five patients were treated. The median size of the tumor was 10 mm (range 7-14). Of the five patients, three underwent an additional session. The median volume of ethanol injection per session was 0.8 (range: 0.3-1.0) mL, and the total was 1.0 (0.9-1.8) mL. Complete ablation at 1 month was achieved in 4 of the 5 tumors (80%). During one year of follow-up, none of the patients reported any procedure-related adverse events, and no malignancy or lymph node metastasis was noted.

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1)Severe allergy history against medical drug 2)Allergy for contrast medium 3)Allergy for ethanol 4)Cases that could not visualize or puncture by using EUS 5)Cases that were diagnosed NEC from a core biopsy specimen obtained by EUS-FNA(WHO2010 classification) 6)Located near the main pancreatic duct 7)PT<=50% or INR>=1.5 8)PLT<=50,000/uL 9)eGFR<=30 mL/min 10)Patients who administered more than 2 anti-thrombotic agent 11)Patients with performance status 2-4. 12)Patients with poor prognosis (less than 3-year) 13)Age<20 14)Patients without informed consent 15)Patients who are judged inappropriate by chief medical examiner

研究者

相似试验